Skip to main content

Clinical validation of the DiviTum assay in two high profile clinical studies in Europe

Deliverables

White Paper

"Publication of a ""White Paper"" and official document summarizing Biovicas perspective on biomarkers, the scientific rationale of the project and including DiviTum as a biomarker and Companion Dx to specific drugs and in clinical trial programmes."

Searching for OpenAIRE data...

Publications

Serum Thymidine Kinase 1 Activity as a Pharmacodynamics Marker of Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Early Stage Breast Cancer Receiving Neoadjuvant Palbociclib

Author(s): Shana Thomas1, Ning Liu1, Rosy (Jingqin) Luo1, Jeremy Hoog1, Mattias Bergqvist2, Magnus Neumüller2, Edward M. Suh2, Zhanfang Guo1, Kiran Vij1, Souzan Sanati1, Matthew Ellis3, Cynthia X. Ma1 1Washington University School of Medicine, St. Louis, MO, 63110; 2 Biovica International AB, Uppsala, Sweden, 3Baylor College of Medicine, Houston, TX, 77030
Published in: San Antonio Breast Cancer Symposium, SABCS 2016, Abstract P5-04-02, Issue ANNUAL, 2016